Friday 20 July 2012

 Improve quality of patient care through IndusMD e-Prescribing











    
IndusMD provides e-Prescribing services to its clients through DrFirst’s Rcopia which was awarded the prestigious Surescripts Gold Solution Provider Certification for 4 Years in a row. Black Book Survey 2013 has ranked DrFirst as #1 e-Prescribing solution.

With IndusMD-Rcopia e-Prescribing meet the following core requirements:
  • Maintain a complete active medication list 
  • Select medications, print prescriptions and electronically transmit prescriptions to any pharmacy in USA
  • Receive all safety alerts (drug-drug interactions, drug-allergy concerns and various other warnings(or) cautions)
  • Receive information related to the lower cost and therapeutically appropriate alternatives 
  • Get info on formulary medications and patient eligibility

With “All scripts” and “free” e-Prescribing Options, clinicians are facing issues like hard to find pharmacies, or sending prescriptions to mail order pharmacies, preventing signature instruction errors, and data server crashes. All these issues can be overcome completely by IndusMD-Rcopia e-prescribing solution.

The best part of IndusMD-Rcopia is it’s compatibility with most used mobile browsing devices such as  iPad and iPhone. Medical Practitioners can access IndusMD-Rcopia through a tablet PC during the consultation with Patient.

IndusMD Rcopia e-Prescribing software is very easy to learn and use. Patient safety, significant error reduction, efficiency, less data entry and less repetitive work are just few of the benefits that IndusMD-Rcopia electronic prescribing can offer to a clinical practice.

Testimonials:

·         "I have been using Rcopia e-prescribing for 3 years through BCBS of Michigan and find the system to be very "user friendly" and comfortable for me and my staff to use."  ---- R. M. Soderstrom, M.D.

·         "[Rcopia] has facilitated medication reconciliation in my office, a process to ensure patient safety." --Dr. Beth Fisher, Christiana Care

No comments:

Post a Comment